Left Atrial Appendage Closure With the Watchman Device in Patients With a Contraindication for Oral Anticoagulation The ASAP Study (ASA Plavix Feasibility Study With Watchman Left Atrial Appendage Closure Technology)

被引：558

作者：

Reddy, Vivek Y. ^{[1
]}

Moebius-Winkler, Sven ^{[2
]}

Miller, Marc A. ^{[1
]}

Neuzil, Petr ^{[3
]}

Schuler, Gerhard ^{[2
]}

Wiebe, Jens ^{[4
]}

Sick, Peter ^{[5
]}

Sievert, Horst ^{[4
]}

机构：

[1] Mt Sinai Sch Med, Helmsley Electrophysiol Ctr, New York, NY 10029 USA

[2] Univ Leipzig, Ctr Heart, D-04109 Leipzig, Germany

[3] Homolka Hosp, Dept Cardiol, Prague, Czech Republic

[4] CardioVasc Ctr Frankfurt, Frankfurt, Germany

[5] Krankenhaus Barmherzigen Bruder, Regensburg, Germany

来源：

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY | 2013年 / 61卷 / 25期

关键词：

atrial fibrillation; left atrial appendage closure; stroke; RANDOMIZED CONTROLLED-TRIAL; STROKE RISK STRATIFICATION; TRANSCATHETER OCCLUSION; FIBRILLATION PATIENTS; HEART-ASSOCIATION; WARFARIN THERAPY; PREVENTION; ASPIRIN; CLOPIDOGREL; POPULATION;

D O I：

10.1016/j.jacc.2013.03.035

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Objectives The purpose of this study was to assess the safety and efficacy of left atrial appendage (LAA) closure in nonvalvular atrial fibrillation (AF) patients ineligible for warfarin therapy. Background The PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients With Atrial Fibrillation) trial demonstrated that LAA closure with the Watchman device (Boston Scientific, Natick, Massachusetts) was noninferior to warfarin therapy. However, the PROTECT AF trial only included patients who were candidates for warfarin, and even patients randomly assigned to the LAA closure arm received concomitant warfarin for 6 weeks after Watchman implantation. Methods A multicenter, prospective, nonrandomized study was conducted of LAA closure with the Watchman device in 150 patients with nonvalvular AF and CHADS(2) (congestive heart failure, hypertension, age >= 75 years, diabetes mellitus, and prior stroke or transient ischemic attack) score >= 1, who were considered ineligible for warfarin. The primary efficacy endpoint was the combined events of ischemic stroke, hemorrhagic stroke, systemic embolism, and cardiovascular/unexplained death. Results The mean CHADS(2) score and CHA(2)DS(2)-VASc (CHADS(2) score plus 2 points for age >= 75 years and 1 point for vascular disease, age 65 to 74 years, or female sex) score were 2.8 +/- 1.2 and 4.4 +/- 1.7, respectively. History of hemorrhagic/bleeding tendencies (93%) was the most common reason for warfarin ineligibility. Mean duration of follow-up was 14.4 +/- 8.6 months. Serious procedure-or device-related safety events occurred in 8.7% of patients (13 of 150 patients). All-cause stroke or systemic embolism occurred in 4 patients (2.3% per year): ischemic stroke in 3 patients (1.7% per year) and hemorrhagic stroke in 1 patient (0.6% per year). This ischemic stroke rate was less than that expected (7.3% per year) based on the CHADS(2) scores of the patient cohort. Conclusions LAA closure with the Watchman device can be safely performed without a warfarin transition, and is a reasonable alternative to consider for patients at high risk for stroke but with contraindications to systemic oral anticoagulation. (C) 2013 by the American College of Cardiology Foundation

引用

页码：2551 / 2556

页数：6

共 26 条

[1]

Bayard YL, 2010, EUROINTERVENTION, V6, P220, DOI 10.4244/

[2] Percutaneous Left Atrial Appendage Occlusion for Patients in Atrial Fibrillation Suboptimal for Warfarin Therapy 5-Year Results of the PLAATO (Percutaneous Left Atrial Appendage Transcatheter Occlusion) Study [J].

Block, Peter C. ;

Burstein, Steven ;

Casale, Paul N. ;

Kramer, Paul H. ;

Teirstein, Paul ;

Williams, David O. ;

Reisman, Mark .

JACC-CARDIOVASCULAR INTERVENTIONS, 2009, 2 (07) :594-600

[3] 2012 focused update of the ESC Guidelines for the management of atrial fibrillation [J].

Camm, A. John ;

Lip, Gregory Y. H. ;

De Caterina, Raffaele ;

Savelieva, Irene ;

Atar, Dan ;

Hohnloser, Stefan H. ;

Hindricks, Gerhard ;

Kirchhof, Paulus ;

Bax, Jeroen J. ;

Baumgartner, Helmut ;

Ceconi, Claudio ;

Dean, Veronica ;

Deaton, Christi ;

Fagard, Robert ;

Funck-Brentano, Christian ;

Hasdai, David ;

Hoes, Arno ;

Knuuti, Juhani ;

Kolh, Philippe ;

McDonagh, Theresa ;

Moulin, Cyril ;

Popescu, Bogdan A. ;

Reiner, Zeljko ;

Sechtem, Udo ;

Sirnes, Per Anton ;

Tendera, Michal ;

Torbicki, Adam ;

Vahanian, Alec ;

Windecker, Stephan ;

Vardas, Panos ;

Al-Attar, Nawwar ;

Alfieri, Ottavio ;

Angelini, Annalisa ;

Blomstrom-Lundqvist, Carina ;

Colonna, Paolo ;

De Sutter, Johan ;

Ernst, Sabine ;

Goette, Andreas ;

Gorenek, Bulent ;

Hatala, Robert ;

Heidbuchel, Hein ;

Heldal, Magnus ;

Kristensen, Steen Dalby ;

Le Heuzey, Jean-Yves ;

Mavrakis, Hercules ;

Mont, Lluis ;

Filardi, Pasquale Perrone ;

Ponikowski, Piotr ;

Prendergast, Bernard ;

Rutten, Frans H. .

EUROPEAN HEART JOURNAL, 2012, 33 (21) :2719-2747

[4] Rationale and design of ACTIVE: The atrial fibrillation clopidogrel trial with irbesartan for prevention of vascular events [J].

Connolly, S. ;

Yusuf, S. ;

Budaj, A. ;

Camm, J. ;

Chrolavicius, S. ;

Commerford, P. J. ;

Flather, M. ;

Fox, K. A. A. ;

Hart, R. ;

Hohnloser, S. ;

Joyner, C. ;

Pfeffer, M. ;

Anand, I. ;

Arthur, H. ;

Avezum, A. ;

Bethala-Sithya, M. ;

Blumenthal, M. ;

Ceremuzynski, L. ;

De Caterina, R. ;

Diaz, R. ;

Flaker, G. ;

Frangin, G. ;

Franzosi, M. -G. ;

Gaudin, C. ;

Golitsyn, S. ;

Goldhaber, S. ;

Granger, C. ;

Halon, D. ;

Hermosillo, A. ;

Hunt, D. ;

Jansky, P. ;

Karatzas, N. ;

Keltai, M. ;

Lanas, F. ;

Lau, C. P. ;

Le Heuzey, J. -Y. ;

Lewis, B. S. ;

Morais, J. ;

Morillo, C. ;

Oto, A. ;

Paolasso, E. ;

Peters, R. J. ;

Pfisterer, M. ;

Piegas, L. ;

Pipillis, T. ;

Proste, C. ;

Sitkei, E. ;

Swedberg, K. ;

Synhorst, D. ;

Talajic, M. .

AMERICAN HEART JOURNAL, 2006, 151 (06) :1187-1193

[5] Effect of Clopidogrel Added to Aspirin in Patients with Atrial Fibrillation [J].

Connolly, S. J. ;

Yusuf, S. ;

Camm, J. ;

Chrolavicius, S. ;

Commerford, P. ;

Flather, M. ;

Hart, R. G. ;

Hohnloser, S. H. ;

Joyner, C. ;

Pfeffer, M. ;

Gaudin, C. ;

Blumenthal, M. ;

Marchese, C. ;

Pogue, J. ;

Hart, R. ;

Hohnloser, S. ;

Anand, I. ;

Arthur, H. ;

Avezum, A. ;

Budaj, A. ;

Ceremuzynski, L. ;

De Caterina, R. ;

Diaz, R. ;

Dorian, P. ;

Flaker, G. ;

Fox, K. A. A. ;

Franzosi, M. G. ;

Goldhaber, S. ;

Golitsyn, S. ;

Granger, C. ;

Halon, D. ;

Hermosillo, A. ;

Hunt, D. ;

Jansky, P. ;

Karatzas, N. ;

Keltai, M. ;

Kozan, O. ;

Lanas, F. ;

Lau, P. ;

Le Heuzey, J. Y. ;

Lewis, B. S. ;

Morais, J. ;

Morillo, C. ;

Paolasso, E. ;

Peters, R. J. ;

Pfisterer, M. ;

Piegas, L. ;

Pipilis, A. ;

Sitkei, E. ;

Swedberg, K. .

NEW ENGLAND JOURNAL OF MEDICINE, 2009, 360 (20) :2066-2078

[6] Apixaban in Patients with Atrial Fibrillation [J].

Connolly, Stuart J. ;

Eikelboom, John ;

Joyner, Campbell ;

Diener, Hans-Christoph ;

Hart, Robert ;

Golitsyn, Sergey ;

Flaker, Greg ;

Avezum, Alvaro ;

Hohnloser, Stefan H. ;

Diaz, Rafael ;

Talajic, Mario ;

Zhu, Jun ;

Pais, Prem ;

Budaj, Andrzej ;

Parkhomenko, Alexander ;

Jansky, Petr ;

Commerford, Patrick ;

Tan, Ru San ;

Sim, Kui-Hian ;

Lewis, Basil S. ;

Van Mieghem, Walter ;

Lip, Gregory Y. H. ;

Kim, Jae Hyung ;

Lanas-Zanetti, Fernando ;

Gonzalez-Hermosillo, Antonio ;

Dans, Antonio L. ;

Munawar, Muhammad ;

O'Donnell, Martin ;

Lawrence, John ;

Lewis, Gayle ;

Afzal, Rizwan ;

Yusuf, Salim .

NEW ENGLAND JOURNAL OF MEDICINE, 2011, 364 (09) :806-817

[7] The increasing incidence of anticoagulant-associated intracerebral hemorrhage [J].

Flaherty, M. L. ;

Kissela, B. ;

Woo, D. ;

Kleindorfer, D. ;

Alwell, K. ;

Sekar, P. ;

Moomaw, C. J. ;

Haverbusch, M. ;

Broderick, J. P. .

NEUROLOGY, 2007, 68 (02) :116-121

[8] Selecting patients with atrial fibrillation for anticoagulation - Stroke risk stratification in patients taking aspirin [J].

Gage, BF ;

van Walraven, C ;

Pearce, L ;

Hart, RG ;

Koudstaal, PJ ;

Petersen, P .

CIRCULATION, 2004, 110 (16) :2287-2292

[9] Validation of clinical classification schemes for predicting stroke - Results from the national registry of Atrial Fibrillation [J].

Gage, BF ;

Waterman, AD ;

Shannon, W ;

Boechler, M ;

Rich, MW ;

Radford, MJ .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 285 (22) :2864-2870

[10] Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non-inferiority trial [J].

Holmes, David R. ;

Reddy, Vivek Y. ;

Turi, Zoltan G. ;

Doshi, Shephal K. ;

Sievert, Horst ;

Buchbinder, Maurice ;

Mullin, Christopher M. ;

Sick, Peter .

LANCET, 2009, 374 (9689) :534-542

← 1 2 3 →